IPCA LABORATORIES-Capacity Expansion

EPW Research Foundation SOL PHARMA Export Growth SOL PHARMA manufacturing bulk drug and formulations, closed the financial year ended March 1995 with a net sales of Rs 205 crore, up by 29 per cent from Rs 158 crore in the previous year. Total income rose by 22 per cent from Rs 173 crore to Rs 210 crore. Interest costs fell by 2 per cent. Provision for depreciation and tax rose by 33 per cent and 148 per cent, respectively, doing little harm to the company's bottomline which moved to Rs 16 crore, a rise of 84 per cent from Rs 8 crore recorded in the previous year. A dividend of 30 per cent has been recommended by the company which has a track record of uninterrupted dividend payment since inception.